Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: A retrospective study

Diseases of the Esophagus

Volumn 21, Issue 6, 2008, Pages 496-501

  Fujita, Y ^a   Hiramatsu, M ^a   Kawai, M ^a   Sumiyoshi, K ^a   Nishimura, H ^a   Tanigawa, Nobuhiko ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Chemotherapy; Docetaxel; Nedaplatin; Recurrent esophageal cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUOROURACIL; NEDAPLATIN; UFT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTPATIENT CARE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 51249121544     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00806.x     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
2. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan Editorial Board. Tokyo, Japan: National Cancer Center, 2003.
3. Enzinger P C, Mayer R J. Esophageal cancer. N Engl J Med 2003; 349: 2241-52.
4. Tew W P, Kelsen D P, Ilson D H. Targeted therapies for esophageal cancer. Oncologist 2005; 10: 590-601.
5. Fujita H, Sueyoshi S, Tanaka T, Shirouzu K. Three-field dissection for squamous cell carcinoma in the thoracic esophagus. Ann Thorac Cardiovasc Surg 2002; 8: 328-35.
6. Registration Committee for Esophageal Cancer. In: Comprehensive Registry of Esophageal Cancer in Japan (1998, 1999) and Long-Term Results of Esophagectomy for Esophageal Cancer in Japan (1988-97), 3rd edn. Tokyo: Japanese Society for Esophageal Dieseases, 2002.
7. Mariette C, Balon J M, Piessen G, Fabre S, Van Seuningen I, Triboulet J P. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616-23.
8. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004; 198: 205-11.
9. Iizuka T, Kakegawa T, Ide H etal. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992; 22: 172-6.
10. Hayashi K, Ando N, Watanabe H et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001; 31: 419-23.
11. Bleiberg H, Conroy T, Paillot B et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33: 1216-20.
12. Ringel I, Horwitz S B. Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-91.
13. Diaz J F, Andreu J M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747-55.
14. Heath E I, Urba S, Marshall J, Piantadosi S, Forastiere A A. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 2002; 20: 95-9.
15. Muro K, Hamaguchi T, Ohtsu A et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15: 955-9.
16. Jingu K, Nemoto K, Matsushita H et al. Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer 2006; 6: 50.
17. Yamashita H, Nakagawa K, Tago M et al. Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: A retrospective study. Dis Esophagus 2006; 19: 15-9.
18. Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis Esophagus 2006; 19: 473-6.
19. Yoshioka T, Sakayori M, Kato S et al. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 2006; 11: 454-60.
20. Therasse P, Arbuck S G, Eisenhauer E A etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
21. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/forms/ CTCAEv3.pdf (accessed 11 December, 2006).
22. Taxotere (package insert). Bridgewater, NJ: Sanofi-aventis U.S. LLC, 2006.
23. Laack E, Andritzky B, Durk H et al. Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: A pilot study. Onkologie 2005; 28: 647-50.
24. Airoldi M, Cortesina G, Giordano C, Pedani F, Bumma C, Gabriele P. Docetaxel and vinorelbine: An effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 2003; 20: 19-24.
25. Lorenzen S, Duyster J, Lersch C et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: Final results of a phase II trial. Br J Cancer 2005; 92: 2129-33.
26. Taguchi T, Wakui A, Nabeya K etal. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group. Gan Kagaku Ryoho 1992; 19: 483-8.
27. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 2004; 40: 1000-6.
28. Yamada H, Maki H, Takeda Y, Orita S. Evaluation of combined nedaplatin and docetaxel therapy for human head and neck cancer in vivo. Anticancer Res 2006; 26: 989-94.